Investors & Media

Press Releases


 
Press Releases
  Date Title View
Jan 3, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company is scheduled to present at the J.P. Morgan 2017 Healthcare Conference in ...
Dec 29, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will participate in a fireside chat at ...
Dec 19, 2016
First patient dosed in Phase 2 proof-of-concept trial of SAGE-217 in major depressive disorder and trial sites open for Phase 2 trial of SAGE-217 in postpartum depression Four Phase 2 clinical programs now underway for SAGE-217 in mood and movement disorders CAMBRIDG...
Dec 13, 2016
First patient dosed in Phase 2 proof-of-concept trial of SAGE-217 in Parkinson's disease Trial sites are open and screening patients for the Phase 2a trial in essential tremor; patients expected to be dosed imminently CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ...
Dec 7, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it will webcast its R&D Day on Tuesday, December 13, 2016 from 12:30 p.m. to 3:30 p.m. ET ...
Dec 6, 2016
Current SAGE-547 clinical program is designed to support potential NDA submission; no additional controlled studies anticipated The current trials will be expanded to Phase 3 trials to facilitate potential for global registration If successfully developed, SAGE-547 has the potentia...
Dec 1, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations at the American Epilepsy Society (AES) 70th Annual Meeting, tak...
Nov 16, 2016
New EMA regulatory designation offers potential for increased dialogue and accelerated assessment of future EU regulatory application Decision based on positive placebo-controlled Phase 2 results SAGE PPD studies in moderate and severe PPD ongoing with top-line results expected in ...
Nov 10, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations at the Society for Neuroscience (SFN) 2016 Annual Meeting, taking place ...
Nov 9, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will present at the Stifel 2016 ...
FirstPrevious
3
... NextLast
= add release to Briefcase